[go: up one dir, main page]

WO2004015390A2 - Proteines cibles du cancer du poumon et utilisations associees - Google Patents

Proteines cibles du cancer du poumon et utilisations associees Download PDF

Info

Publication number
WO2004015390A2
WO2004015390A2 PCT/US2003/024698 US0324698W WO2004015390A2 WO 2004015390 A2 WO2004015390 A2 WO 2004015390A2 US 0324698 W US0324698 W US 0324698W WO 2004015390 A2 WO2004015390 A2 WO 2004015390A2
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
peptide
peptides
proteins
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/024698
Other languages
English (en)
Other versions
WO2004015390A3 (fr
Inventor
Stephen Hoffman
Ruobing Wang
Gangadharan Subramanian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Biosystems Inc
Original Assignee
Applera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applera Corp filed Critical Applera Corp
Priority to AU2003258134A priority Critical patent/AU2003258134A1/en
Publication of WO2004015390A2 publication Critical patent/WO2004015390A2/fr
Anticipated expiration legal-status Critical
Publication of WO2004015390A3 publication Critical patent/WO2004015390A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G01N33/5752—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the present invention also provides peptide sequences for MHC or HLA class LT-restricted epitopes (restricting allele) from HLA-DR*0101 and HLA- DR*0401 that may serve as specific targets of T lymphocytes.
  • the peptides of the present invention also are utilized as therapeutic T cell vaccines themselves or as components of a polyepitope therapeutic T cell vaccine.
  • FIGURE 6 B-cell epitopes/peptides for making immunogenic antibodies.
  • the peptides of present invention can be modified to increase immunogenicity by enhancing binding of a peptide to the MHC molecule with which the peptide is associated.
  • modification may include substitution, deletion or addition of an amino acid in the given immunogenic peptide sequence or mutation of existing amino acids within the given immunogenic peptide sequence, or derivatization of existing amino acids within the given immunogenic peptide sequence.
  • Any amino acid comprising the immunogenic peptide sequence may be modified in accordance with this invention.
  • at least one amino acid is substituted or replaced within the given immunogenic peptide sequence. Any amino acid may be used to substitute or replace a given amino acid within the immunogenic peptide sequence.
  • Modified peptides are intended to include any immunogenic peptide obtained from differentially expressed proteins, which has been modified and exhibits enhanced binding to the MHC molecule with which it associates when presented to the T-cell.
  • TTLs cytotoxic T lymphocytes
  • PBMCs periperal blood mononuclear cells
  • TILs tumor infiltrating lymphocytes
  • a response is considered positive if the mean of interferon gamma spot forming cells in triplicate or quadruplicate experimental wells is significantly greater than the mean of interferon gamma spot forming cells (SFCs) in control wells (p ⁇ 0.05), the ratio of SFCs in experimental vs control wells is greater than 2, and the difference between SFCs in experimental vs control wells is greater than 5 SFCs.
  • SFCs interferon gamma spot forming cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne cinq protéines cibles du cancer du poumon qui sont exprimées de manière différentielle dans des cellules ou des tissus du cancer du poumon. L'invention concerne également une méthode de détection du cancer du poumon. L'invention concerne en outre un vaccin de prévention et de traitement du cancer du poumon. Ce vaccin comprend des peptides immunogènes dérivés desdites cinq protéines et analogues de celles-ci. L'invention concerne enfin des anticorps qui ciblent de manière spécifique les protéines du cancer du poumon, et leur utilisation diagnostique et thérapeutique.
PCT/US2003/024698 2002-08-09 2003-08-08 Proteines cibles du cancer du poumon et utilisations associees Ceased WO2004015390A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003258134A AU2003258134A1 (en) 2002-08-09 2003-08-08 Lung cancer target proteins and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40205702P 2002-08-09 2002-08-09
US60/402,057 2002-08-09

Publications (2)

Publication Number Publication Date
WO2004015390A2 true WO2004015390A2 (fr) 2004-02-19
WO2004015390A3 WO2004015390A3 (fr) 2007-12-13

Family

ID=31715780

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/024698 Ceased WO2004015390A2 (fr) 2002-08-09 2003-08-08 Proteines cibles du cancer du poumon et utilisations associees

Country Status (2)

Country Link
AU (1) AU2003258134A1 (fr)
WO (1) WO2004015390A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2010037514A3 (fr) * 2008-10-01 2010-06-03 Immatics Biotechnologies Gmbh Nouvelle immunothérapie dirigée contre plusieurs tumeurs, y compris des tumeurs neuronales et cérébrales
US20130045212A1 (en) * 2009-03-13 2013-02-21 Kim Suzanne Midwood Biological Materials and Uses Thereof
WO2017089761A1 (fr) * 2015-11-23 2017-06-01 Immunocore Limited Peptides dérivés de la protéine 8 de type active (actl8)
WO2020094797A1 (fr) * 2018-11-07 2020-05-14 Follicum Ab Fragments peptidiques pour le traitement du diabète
US10980893B2 (en) 2015-11-23 2021-04-20 Immunocore Limited Peptides derived from transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to MHC molecules

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008431B2 (en) * 2004-05-25 2011-08-30 Immatics Biotechnologies Gmbh Tumor-associated peptides that bind to MHC-molecules
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US10100085B2 (en) 2008-10-01 2018-10-16 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including neuronal and brain tumors
US10047123B2 (en) 2008-10-01 2018-08-14 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including neuronal and brain tumors
US8119139B2 (en) 2008-10-01 2012-02-21 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including neuronal and brain tumors
WO2010037514A3 (fr) * 2008-10-01 2010-06-03 Immatics Biotechnologies Gmbh Nouvelle immunothérapie dirigée contre plusieurs tumeurs, y compris des tumeurs neuronales et cérébrales
US8961985B2 (en) 2008-10-01 2015-02-24 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including neuronal and brain tumors
EA023013B1 (ru) * 2008-10-01 2016-04-29 Имматикс Байотекнолоджиз Гмбх Пептид, индуцирующий противоопухолевый иммунный ответ, и его применение
CN102170900B (zh) * 2008-10-01 2016-10-26 伊玛提克斯生物技术有限公司 抗神经元和脑肿瘤等几种肿瘤的新型免疫疗法
US12234298B2 (en) 2008-10-01 2025-02-25 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including neuronal and brain tumors
US9993540B2 (en) 2008-10-01 2018-06-12 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including neuronal and brain tumors
US11136352B2 (en) 2008-10-01 2021-10-05 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including neuronal and brain tumors
US10046037B2 (en) 2008-10-01 2018-08-14 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including neuronal and brain tumors
US12221493B2 (en) 2008-10-01 2025-02-11 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including neuronal and brain tumors
CN102170900A (zh) * 2008-10-01 2011-08-31 伊玛提克斯生物技术有限公司 抗神经元和脑肿瘤等几种肿瘤的新型免疫疗法
US10227381B2 (en) 2008-10-01 2019-03-12 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including neuronal and brain tumors
US10047124B2 (en) 2008-10-01 2018-08-14 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including neuronal and brain tumors
US11208434B2 (en) 2008-10-01 2021-12-28 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including neuronal and brain tumors
US10906936B2 (en) 2008-10-01 2021-02-02 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including neuronal and brain tumors
US10919931B2 (en) 2008-10-01 2021-02-16 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including neuronal and brain tumors
US10941181B2 (en) 2008-10-01 2021-03-09 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including neuronal and brain tumors
US20130045212A1 (en) * 2009-03-13 2013-02-21 Kim Suzanne Midwood Biological Materials and Uses Thereof
US10980893B2 (en) 2015-11-23 2021-04-20 Immunocore Limited Peptides derived from transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to MHC molecules
US10792333B2 (en) 2015-11-23 2020-10-06 Immunocore Limited Peptides derived from actin-like protein 8 (ACTL8)
WO2017089761A1 (fr) * 2015-11-23 2017-06-01 Immunocore Limited Peptides dérivés de la protéine 8 de type active (actl8)
CN113164548A (zh) * 2018-11-07 2021-07-23 富力卡姆股份公司 用于治疗糖尿病的肽片段
JP2022516400A (ja) * 2018-11-07 2022-02-28 フォリクム エービー 糖尿病治療のためのペプチド断片
JP7553115B2 (ja) 2018-11-07 2024-09-18 フォリクム エービー 糖尿病治療のためのペプチド断片
WO2020094797A1 (fr) * 2018-11-07 2020-05-14 Follicum Ab Fragments peptidiques pour le traitement du diabète

Also Published As

Publication number Publication date
AU2003258134A1 (en) 2004-02-25
AU2003258134A8 (en) 2004-02-25
WO2004015390A3 (fr) 2007-12-13

Similar Documents

Publication Publication Date Title
US7879981B2 (en) Breast, gastric and prostate cancer associated antigens and uses therefor
US6630326B2 (en) Cancer diagnosis and therapy based on mutations in TGF-β receptors
EP1992640A1 (fr) Composés pour l'immunothérapie et le diagnostic du cancer du sein et leurs procédés d'utilisation
JP6259320B2 (ja) ヒト非小細胞肺癌における転座及び変異体ｒｏｓキナーゼ
US20140363831A1 (en) Compounds and methods useful for detection and treatment of cancer
EP1259812A2 (fr) Antigenes associes au cancer du sein, de la prostate et de l'estomac et leur utilisation
AU2344399A (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
JP2006201187A (ja) 前立腺ガンの免疫診断のための化合物およびそれらの使用方法
WO1997008318A2 (fr) Composes et procedes de traitement et de diagnostic du cancer de la prostate
JP2009540852A (ja) 前立腺特異的な転写物ならびに前立腺癌の治療および診断におけるその使用
US6410507B1 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
US20050221305A1 (en) Antigen panels and methods of using the same
JP2002534356A (ja) 乳疾患の検出に有用な試薬及び方法
US20060134668A1 (en) Methods for treating patients and identifying therapeutics
US6387697B1 (en) Compositions for treatment and diagnosis of breast cancer and methods for their use
WO2004015390A2 (fr) Proteines cibles du cancer du poumon et utilisations associees
US9134314B2 (en) Methods for diagnosing and treating cancers
US20050214798A1 (en) Bridging integrator-2 (Bin2) nucleic acid molecules and proteins and uses therefor
US6379951B1 (en) Compounds for immunotherapy of breast cancer and methods for their use
CA2643737C (fr) Vaccin contre le cancer
EP1705487A2 (fr) Procédé de diagnostic, de contrôle, de détermination du stade, d'imagerie et de traitement du cancer du colon
WO2001016158A2 (fr) Molecules d'acide nucleique et proteines d'integrateur 2 de pontage et utilisations associees
JP2009195236A (ja) 乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法
HK1132911B (en) Cancer vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP